Vertex faces first notable setback as it pushes beyond cystic fibrosis

Vertex faces first notable setback as it pushes beyond cystic fibrosis

Source: 
BioPharma Dive
snippet: 

Vertex Pharmaceuticals said Wednesday it will stop working on a closely watched experimental drug because of safety signals seen in a mid-stage study.
The study was testing Vertex's drug, VX-814, in patients with an inherited disorder that leaves them with too little of a lung-protecting protein called alpha-1 antitrypsin, or AAT.